Published in Nat Rev Nephrol on January 20, 2015
Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 0.97
Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol (2016) 0.76
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol (2016) 0.76
Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. J Am Soc Nephrol (2016) 0.75
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J (2017) 0.75
The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol (2017) 0.75
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science (2005) 7.03
Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature (1999) 6.85
Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem (2001) 6.42
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol (2007) 4.31
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol (2007) 3.23
The nephrotic syndrome. N Engl J Med (1998) 3.22
Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol (2011) 3.05
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol (2006) 2.32
Activation of platelet function through G protein-coupled receptors. Circ Res (2006) 2.13
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int (2013) 2.13
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol (2012) 1.93
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr (2001) 1.84
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant (2012) 1.60
Experimental membranous nephropathy redux. Am J Physiol Renal Physiol (2005) 1.52
Diacylglycerol kinase epsilon regulates seizure susceptibility and long-term potentiation through arachidonoyl- inositol lipid signaling. Proc Natl Acad Sci U S A (2001) 1.51
Regulation and functions of diacylglycerol kinases. Chem Rev (2011) 1.48
Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation. Exp Biol Med (Maywood) (2011) 1.47
A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C gamma2 in platelets independent of the integrin alpha2beta1. Blood (1997) 1.45
Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest (2002) 1.28
The regulation of aortic endothelial cells by purines and pyrimidines involves co-existing P2y-purinoceptors and nucleotide receptors linked to phospholipase C. Br J Pharmacol (1993) 1.25
Thrombin and histamine activate phospholipase C in human endothelial cells via a phorbol ester-sensitive pathway. J Cell Physiol (1988) 1.21
Platelet receptor signaling in thrombus formation. J Mol Med (Berl) (2010) 1.20
Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease. PLoS One (2010) 1.18
DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest (2003) 1.18
Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J Am Soc Nephrol (2007) 1.16
The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids (2013) 1.15
Mediation of immune glomerular injury. J Am Soc Nephrol (1990) 1.14
A diacylglycerol kinase inhibitor, R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets. Biochem J (1987) 1.14
A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin Nephrol (2006) 1.14
Fluid shear stress stimulates membrane phospholipid metabolism in cultured human endothelial cells. J Vasc Res (1993) 1.12
Hemolytic uremic syndrome. Semin Immunopathol (2014) 1.12
Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant (2013) 1.11
Diacylglycerol kinase epsilon is selective for both acyl chains of phosphatidic acid or diacylglycerol. J Biol Chem (2009) 1.10
The alpha2beta1 integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase Cgamma2 in platelets. J Biol Chem (1996) 1.10
The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol (2007) 1.08
Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol (2011) 1.08
NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury. Cell Physiol Biochem (2009) 1.07
Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol (2000) 1.05
Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem (2002) 1.04
Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal Physiol (2011) 1.04
C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. Kidney Int (1990) 1.04
Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood (2014) 0.99
Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol (2012) 0.96
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 0.95
Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2014) 0.94
Angiotensin II activation of TRPC6 channels in rat podocytes requires generation of reactive oxygen species. J Cell Physiol (2014) 0.93
The roles of protein kinase C and intracellular Ca2+ in the secretion of von Willebrand factor from human vascular endothelial cells. Biochem J (1992) 0.93
The glomerulus--a view from the inside--the endothelial cell. Int J Biochem Cell Biol (2010) 0.93
Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol (2014) 0.93
Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol (2012) 0.93
Angiotensin II-elicited signal transduction via AT1 receptors in endothelial cells. Br J Pharmacol (1996) 0.92
Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost (2012) 0.91
Complement activates phospholipases and protein kinases in glomerular epithelial cells. Kidney Int (1998) 0.91
Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Ren Fail (1998) 0.91
Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis (2000) 0.91
Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int (2010) 0.91
The role of complement in membranous nephropathy. Semin Nephrol (2013) 0.90
Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells. Am J Physiol Endocrinol Metab (2000) 0.90
Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol (2013) 0.90
Activation of phospholipase A2 by complement C5b-9 in glomerular epithelial cells. J Immunol (1997) 0.89
NOX2 interacts with podocyte TRPC6 channels and contributes to their activation by diacylglycerol: essential role of podocin in formation of this complex. Am J Physiol Cell Physiol (2013) 0.88
Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells : role of cyclooxygenase-1 and -2. Am J Pathol (2000) 0.88
An adult with acute poststreptococcal glomerulonephritis complicated by hemolytic uremic syndrome and nephrotic syndrome. Am J Kidney Dis (2005) 0.88
Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr Nephrol (2008) 0.87
Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism? Thromb Haemost (2010) 0.86
Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of hemolytic uremic syndrome with glomerular disease. Intern Med (1999) 0.86
Complement-induced phospholipase A2 activation in experimental membranous nephropathy. Kidney Int (2000) 0.86
A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol (2014) 0.85
Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome. Am J Nephrol (2007) 0.85
Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract (2004) 0.85
Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol (2006) 0.85
Proteolytic activation of protein kinase Calpha by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein. Biochemistry (2005) 0.84
Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J Pharmacol Exp Ther (2003) 0.84
Chelerythrine, a selective protein kinase C inhibitor, counteracts pyrogen-induced expression of tissue factor without effect on thrombomodulin down-regulation in endothelial cells. Thromb Res (1993) 0.84
Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail (2014) 0.83
Molecular species of phosphatidylinositol-cycle intermediates in the endoplasmic reticulum and plasma membrane. Biochemistry (2010) 0.83
Substrate specificity of diacylglycerol kinase-epsilon and the phosphatidylinositol cycle. FEBS Lett (2011) 0.83
Role of protein kinase C in the regulation of prostaglandin synthesis in human endothelium. Am J Respir Cell Mol Biol (1992) 0.82
Signal transduction in podocytes--spotlight on receptor tyrosine kinases. Nat Rev Nephrol (2014) 0.82
Hemolytic uremic syndrome associated with glomerular disease. Am J Kidney Dis (1989) 0.81
Cytosolic phospholipase A(2)-alpha enhances induction of endoplasmic reticulum stress. Biochim Biophys Acta (2010) 0.80
What has the immune system got against the glomerular podocyte? Clin Exp Immunol (2003) 0.80
Involvement of endothelial cell adhesion molecules in the development of anti-Thy-1 nephritis. Exp Nephrol (2002) 0.80
The actin cytoskeleton facilitates complement-mediated activation of cytosolic phospholipase A2. Am J Physiol Renal Physiol (2003) 0.78
Hemolytic uremic syndrome associated with Denys-Drash syndrome. Pediatr Nephrol (2000) 0.77
A glimpse of the glomerular milieu: from endothelial cell to thrombotic disease in nephrotic syndrome. Microvasc Res (2013) 0.76
[Postpartum hemolytic uremic syndrome: a rare entity and a treatment challenge]. Nefrologia (2008) 0.75
A patient with thrombotic microangiopathy accompanied by glomerular subendothelial electron dense deposits. Am J Nephrol (1998) 0.75
[Hemolytic and uremic syndrome associated with an idiopathic nephrotic syndrome of 4 years' development]. Ann Pediatr (Paris) (1969) 0.75